Immune Checkpoint Inhibitor–Associated Cardiovascular Toxic Effects
Concerns for myocarditis continue to dominate the spectrum of CV toxic effects in patients receiving ICI therapy. Recommendations for management vary according to severity. Multidisciplinary collaborations remain key for managing acute toxic effects and future cancer treatment decisions, including ICI rechallenge. Ischemic heart disease constitutes the main differential diagnosis in these patients, while pericarditis can be concomitantly present, and atrial and ventricular arrhythmias can also complicate the clinical picture. Several gaps in knowledge are identified and require further research.
Authors
- Teresa López‐Fernández (ORCID: https://orcid.org/0000-0002-3414-7022)
- Joshua D. Mitchell (ORCID: https://orcid.org/0000-0001-7371-5742)
- Richard Kar-Hang Cheng (ORCID: https://orcid.org/0000-0001-5994-5998)
- Elena Deych (ORCID: https://orcid.org/0000-0002-6083-3579)
- Anju Nohria
- Ana Barac (ORCID: https://orcid.org/0000-0002-9935-8904)
- Jennifer Liu (ORCID: https://orcid.org/0000-0002-7177-9758)
- Andrés J. Daniele
- Ariane Vieira Scarlatelli Macedo (ORCID: https://orcid.org/0000-0002-3453-8488)
- Daniel J. Lenihan (ORCID: https://orcid.org/0000-0001-9458-0154)
- Susan Dent (ORCID: https://orcid.org/0000-0002-9183-9340)
- Aaron L. Sverdlov (ORCID: https://orcid.org/0000-0003-2539-8038)
- Giselle Alexandra Suero‐Abreu (ORCID: https://orcid.org/0000-0002-4274-2761)
- Michael G. Fradley (ORCID: https://orcid.org/0000-0001-8352-8975)
- Joseph R. Carver (ORCID: https://orcid.org/0000-0001-8804-0653)
- Charles Porter (ORCID: https://orcid.org/0000-0001-8820-9279)
- Tienush Rassaf
- Darryl P. Leong (ORCID: https://orcid.org/0000-0002-1968-169X)
- Dae Hyun Lee (ORCID: https://orcid.org/0000-0001-8141-0404)
- Meghan J. Mooradian (ORCID: https://orcid.org/0000-0002-8289-8015)
- Tomas G. Neilan (ORCID: https://orcid.org/0000-0002-1513-8833)
- Joerg Herrmann (ORCID: https://orcid.org/0000-0001-6675-4559)
- Paaladinesh Thavendiranathan
- Alexander R Lyon
Institutions
- Inova Health System (US)
- Brigham and Women's Hospital (US)
- Mayo Clinic (US)
- Memorial Sloan Kettering Cancer Center (US)
- University of Washington (US)
- Washington University in St. Louis (US)
- Universidad de Buenos Aires (AR)
- University of South Florida (US)
- Inova Fairfax Hospital (US)
- Toronto General Hospital (CA)
- The University of Kansas Health System (US)
- Population Health Research Institute (CA)
- University of Rochester Medical Center (US)
- Hunter Medical Research Institute (AU)
- Massachusetts General Hospital (US)
- Ted Rogers Centre for Heart Research (CA)
- Royal Brompton Hospital (GB)
- Hospital La Paz Institute for Health Research (ES)
- Saint Francis Medical Center (US)
- Faculdade de Ciências Médicas da Santa Casa de São Paulo (BR)
- Calvary Mater Newcastle Hospital (AU)
- Center for Cancer Research (US)
- West German Heart and Vascular Center Essen (DE)
- University of Pennsylvania (US)
Publication Details
- Journal
- JAMA Oncology
- Published
- 2025-11-13
- DOI
- https://doi.org/10.1001/jamaoncol.2025.4543
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05